Probióticos como alternativa terapêutica na amebíase. Onde estamos?

Autores

DOI:

https://doi.org/10.33448/rsd-v13i10.47039

Palavras-chave:

Entamoeba histoltytica, Probióticos, Protozoáio.

Resumo

Entamoeba histolytica é a causa da amebíase, uma doença tropical negligenciada e uma das principais causas de mortalidade mundial. O objetivo desta revisão é mostrar o potencial dos probióticos como estratégia de tratamento para amebíase. Foi realizada uma busca sistemática no PubMed e Google Scholar com as palavras-chave "Entamoeba histolytica", "amebíase" e "probióticos." Os estudos sobre o uso de probióticos no tratamento da amebíase são limitados, mas alguns apresentaram resultados promissores. O Lactobacillus acidophilus reduziu a excreção de cistos de E. histolytica em 79,67% em camundongos, com eficácia de 68,31%, comparável ao metronidazol. O Bifidobacterium sp. mostrou 75,63% de eficácia na redução da gravidade da infecção, superior ao metronidazol (67,56%). O Lactobacillus salivarius inibiu o crescimento de E. histolytica in vitro e ofereceu proteção in vivo. Lactobacillus fermentum e L. delbrueckii inibiram a proliferação de E. histolytica com eficácia variando de 46,42% a 97,68%, dependendo da concentração. O Saccharomyces boulardii reduziu a duração da disenteria amebiana em 25% e eliminou os cistos parasitários em amostras de fezes humanas. Lactobacillus casei apresentou uma taxa de recuperação de 100% em ratos infectados por E. histolytica. Esses achados sugerem que os probióticos têm potencial terapêutico contra infecções por E. histolytica, destacando a necessidade de mais pesquisas tanto em modelos animais quanto em humanos para validar sua aplicação no tratamento da amebíase.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

Abasszade, J. H., Little, R., Yeaman, F., Robertson, M., & Bell, S. (2021). Amoebic colitis: A case series of a recurring missed diagnosis. JGH Open, 5(3), 404-407.

Adl, S. M., Bass, D., Lane, C. E. et al. (2019). Revisions to the classification, nomenclature, and diversity of eukaryotes. Journal of Eukaryotic Microbiology, 66(1), 4-119.

Al-Tawaha, R., & Meng, C. (2018). Potential benefits of Lactobacillus plantarum as probiotic and its advantages in human health and industrial applications: A review. Adv. Environ. Biol, 12, 16-27.

Birchenough, G. M., Johansson, M. E., Gustafsson, J. K., Bergström, J. H., & Hansson, G. (2015). New developments in goblet cell mucus secretion and function. Mucosal immunology, 8(4), 712-719.

Carrero, J. C., Reyes-López, M., Serrano-Luna, J., Shibayama, M., Unzueta, J., León-Sicairos, N., & de la Garza, M. (2020). Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. International Journal of Medical Microbiology, 310(1), 151358.

Cuellar-Guevara, F. L., Barrón-González, M. P., & Menchaca-Arredondo, J. L. (2019). Effect of Lactobacillus postbiotics on Entamoeba histolytica trophozoites. Revista de investigación clínica, 71(6), 402-407.

Das, M., Biswas, P., & Dam, S. (2024). Isolation and Potential Probiotic Characterization of Lactic Acid Bacteria from an Ethnic Fermented Beverage having Antibacterial Activity against Human Pathogen Entamoeba histolytica. International Journal of Pharmaceutical Investigation, 14(2).

Dinleyici, E., Eren, M., Yargic, Z., DOĞAN, N., & Vandenplas, Y. (2009). Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. American Journal of Tropical Medicine and Hygiene, 80(6).

Flach, J., Van Der Waal, M. B., Kardinaal, A. F. M., Schloesser, J., Ruijschop, R. M. A. J., & Claassen, E. (2018). Probiotic research priorities for the healthy adult population: A review on the health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12. Cogent Food & Agriculture, 4(1), 1452839.

Gomes, I. S. & Caminha, I. O. (2014). Guia para estudos de revisão sistemática: uma opção metodológica para as Ciências do Movimento Humano. Movimento. 20 (1), 395-411.

Guillén, N. (2023). Pathogenicity and virulence of Entamoeba histolytica, the agent of amoebiasis. Virulence, 14(1), 2158656.

Imperato, P. J. (1981). A historical overview of amebiasis. Bulletin of the New York Academy of Medicine, 57(3), 175.

Johansson, M. E., Phillipson, M., Petersson, J., Velcich, A., Holm, L., & Hansson, G. C. (2008). The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proceedings of the national academy of sciences, 105(39), 15064-15069.

Khalaf, K. J. (2013). Study of Lactobacillus acidophilus as atreatment and prophylaxis for Entamoeba histolytica infected mice. World Journal of Pharmaceutical Research, 2(5), 1229-1237.

Kissoon-Singh, V., Moreau, F., Trusevych, E., & Chadee, K. (2013). Entamoeba histolytica exacerbates epithelial tight junction permeability and proinflammatory responses in Muc2−/− mice. The American journal of pathology, 182(3), 852-865.

Lidell, M. E., Moncada, D. M., Chadee, K., & Hansson, G. C. (2006). Entamoeba histolytica cysteine proteases cleave the MUC2 mucin in its C-terminal domain and dissolve the protective colonic mucus gel. Proceedings of the National Academy of Sciences, 103(24), 9298-9303.

Magistrelli, L., Amoruso, A., Mogna, L., Graziano, T., Cantello, R., Pane, M., & Comi, C. (2019). Probiotics may have beneficial effects in Parkinson's disease: in vitro evidence. Frontiers in immunology, 10, 969.

Maldonado Galdeano, C., Cazorla, S. I., Lemme Dumit, J. M., Vélez, E., & Perdigón, G. (2019). Beneficial effects of probiotic consumption on the immune system. Annals of Nutrition and Metabolism, 74(2), 115-124.

Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., & Shafaghi, A. (2003). Efficacy of Saccharomyces boulardii with antibiotics in acute amoebiasis. World journal of gastroenterology: WJG, 9(8), 1832.

Mattos, P. C. (2015). Tipos de revisão de literatura. Unesp, 1-9. https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.pdf 6.1.3).

Mazziotta, C., Tognon, M., Martini, F., Torreggiani, E., & Rotondo, J. C. (2023). Probiotics mechanism of action on immune cells and beneficial effects on human health. Cells, 12(1), 184.

Mohamed, S. T. (2014). Use of Bifidobacterium for Treatment and Protective from Entamoeba Histolytica Infection in Mice. International Journal of Science and Technology, 3(1).

Mohammed, S., Khalaf, K., & Sulaiman, N. (2015). Lactobacillus salivarius bacteriocin and supernatant activity against Entamoeba histolytica in vitro and in vivo. Br J Biol Health Med Sci Res, 3, 19-28.

Moncada, D., Keller, K., & Chadee, K. (2005). Entamoeba histolytica-secreted products degrade colonic mucin oligosaccharides. Infection and immunity, 73(6), 3790-3793.

Montalban-Arques, A., De Schryver, P., Bossier, P., Gorkiewicz, G., Mulero, V., Gatlin III, D. M., & Galindo-Villegas, J. (2015). Selective manipulation of the gut microbiota improves immune status in vertebrates. Frontiers in Immunology, 6, 512.

Morán, P., Serrano-Vázquez, A., Rojas-Velázquez, L., González, E., Pérez-Juárez, H., Hernández, E. G., ... & Ximénez, C. (2023). Amoebiasis: Advances in diagnosis, treatment, immunology features and the interaction with the intestinal ecosystem. International Journal of Molecular Sciences, 24(14), 11755.

Pelaseyed, T., Bergström, J. H., Gustafsson, J. K., Ermund, A., Birchenough, G. M., Schütte, A., ... & Hansson, G. C. (2014). The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunological reviews, 260(1), 8-20.

Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM. 6.1.2).

Rahi, A. A., & Nashaat, Z. (2013). Leaky cells and the use of Lactobacillus casei in the treatment of laboratory animals infected with amoebic dysentery. Euphrates Journal of Agriculture Science, 5(1), 15-22.

Sabti, Z. S., Abbas, S. K., & Mahmood, N. N. (2019). Investigation the Role of Lactobacillus ssp. on Entamoeba histolytica Pathogenesis. Indian Journal of Public Health Research & Development, 10(10).

Samba-Louaka, A., Delafont, V., Rodier, M. H., Cateau, E., & Héchard, Y. (2019). Free-living amoebae and squatters in the wild: ecological and molecular features. FEMS microbiology reviews, 43(4), 415-434.

Sanders, M. E., Guarner, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., ... & Mayer, E. A. (2013). An update on the use and investigation of probiotics in health and disease. Gut, 62(5), 787-796.

Sarao, L. K., & Arora, M. (2017). Probiotics, prebiotics, and microencapsulation: A review. Critical reviews in food science and nutrition, 57(2), 344-371.

Sarid, L., Zanditenas, E., Ye, J., Trebicz-Geffen, M., & Ankri, S. (2022). Insights into the mechanisms of Lactobacillus acidophilus activity against Entamoeba histolytica by using thiol redox proteomics. Antioxidants, 11(5), 814.

Savaş-Erdeve, S., Gökay, S., & Dallar, Y. (2009). Efficacy and safety of Saccharomyces boulardii in amebiasis-associated diarrhea in children. The Turkish Journal of Pediatrics, 51(3), 220-224.

Shafeek, Z., & Ruzzuki, N. (2016). The effect of different concentrations of the run and stuck bacteria (Lactobacillus fermentum, Lactobacillus delbrueckii) in trophozoite growth of Entamoeba histolytica in vitro. Int J Curr Microbiol Appl Sci, 5, 924-30.

Sperandio, B., Fischer, N., & Sansonetti, P. J. (2015). Mucosal physical and chemical innate barriers: Lessons from microbial evasion strategies. In Seminars in immunology, Vol. 27, No. 2, pp. 111-118.

Uribe-Querol, E., & Rosales, C. (2020). Immune response to the enteric parasite Entamoeba histolytica. Physiology, 35(4), 244-260.

Walsh, J. A. (1986). Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Reviews of infectious diseases, 8(2), 228-238.

Whittemore, R., & Knafl, K. (2005). The integrative review: updated methodology. Journal of advanced nursing, 52(5), 546-553.

Downloads

Publicado

2024-10-11

Edição

Seção

Artigos de Revisão

Como Citar

Probióticos como alternativa terapêutica na amebíase. Onde estamos?. Research, Society and Development, [S. l.], v. 13, n. 10, p. e43131047039, 2024. DOI: 10.33448/rsd-v13i10.47039. Disponível em: https://ojs34.rsdjournal.org/index.php/rsd/article/view/47039. Acesso em: 29 jun. 2025.